Law Offices of Thomas J. Lamb

  • Asbestos & Mesothelioma
  • Benzene Diseases
  • Camp Lejeune Cases
  • Drug Injury
  • Free Case Evaluation
  • About Us

Immunotherapy Making Headway in SCLC and Mesothelioma

March 21, 2018 By Law Offices of Thomas J. Lamb, P.A.

Immune-based therapies continue to show promising signals for patients with small cell lung cancer (SCLC) and mesothelioma, but better predictive biomarkers are needed to determine who is most likely to benefit, according to Justin F. Gainor, MD.

The rationale for immunotherapy in SCLC is growing because it is a very molecularly complex disease, Gainor said in a presentation during the 5th Annual Miami Lung Cancer Conference. While PD-L1 expression is infrequent in this space, SCLC tumors can be characterized by relatively high tumor mutation burden (TMB).

“We’ve seen responses with PD-1 monotherapy as well as with dual checkpoint blockade regardless of PD-L1 status,” said Gainor, assistant professor of medicine at Harvard Medical School and an assistant in medicine at Massachusetts General Hospital. “The combination of PD-1/CTLA-4 is associated with a higher response rate compared with nivolumab alone, but this benefit appears to be most pronounced in high TMB patients.”

Signals with checkpoint inhibitors were first reported with pembrolizumab (Keytruda) in the multi-cohort KEYNOTE-028 trial, which showed that the PD-1 inhibitor pembrolizumab was associated with a 33% overall response rate (ORR) in patients with PD-L1-positive SCLC. Of all patients enrolled on the study, 31.7% tested PD-L1 positive, defined as ?1% PD-L1 expression in tumor and inflammatory cells or stroma.

Nivolumab (Opdivo) has also been investigated in several SCLC studies. The open-label, phase I/II CheckMate-032 trial, for example, evaluated 216 patients with progressive SCLC who had received ?1 prior platinum-containing regimen and were not stratified for PD-L1 expression. Patients were randomly assigned to single-agent nivolumab or the combination of nivolumab and ipilimumab (Yervoy) at 1 of 2 doses.

[Article continues at original source]

 Mesothelioma, Asbestos, and Legal Compensation: Basic Facts

Asbestos-Mesothelioma Case Evaluation Form
Free.  Confidential.  No Obligation.

Filed Under: Asbestos, Mesothelioma

Find What You Want Here

Get Free Case Evaluation

We encourage you to submit an online Case Evaluation Form – it is confidential and there is no obligation.

Or call our toll-free number, 800-426-9535, to speak directly to attorney Tom Lamb about your possible case.

Feel Free To Contact Us

Quick Contact Form
 
Send an Email to Tom Lamb

(800) 426-9535

Main Navigation Menu

  • About Our Firm
  • Asbestos-Mesothelioma Cases
  • Benzene Disease Claims
  • PFAS Firefighter Gear Lawsuits
  • Camp Lejeune Cases
  • GenX Water Cancer Cases
  • Drug Injury Lawsuits
  • Breast Implant Cancer Cases
  • Philips Breathing Devices Cases
  • Case Evaluation Menu
  • Quick Contact Form
  • Frequently Asked Questions
  • Medical Records Charges
  • Collection of Articles
  • Sitemap

Lamb Law Office Newsletter

Lamb Law Office Newsletter provides periodic updates about some of the cases that we are working on for clients, as well as an information resource you might find helpful.

Subscribe using Form below.

Subscription Form

* indicates required

Our Other Websites

Drug Injury Law
Drug Injury Watch
Drug Safety Developments
Asbestos & Mesothelioma

Contact Information

Law Offices of Thomas J. Lamb, P.A.
1908 Eastwood Road, Suite 225
Wilmington, North Carolina 28403
910-256-2971 | 800-426-9535
TJL@LambLawOffice.com

  • Home
  • Frequently Asked Questions
  • Disclaimer and Copyright Notices

Copyright © 2023 · Law Offices of Thomas J. Lamb, P.A.